Ebymect

dapagliflozin / metformin

Overview
Authorisation details
Product information
Assessment history

Authorised

This medicine is authorised for use in the European Union.

Overview

Ebymect is a diabetes medicine that is used, together with diet and exercise in adults with type 2 diabetes. It contains the active substances dapagliflozin and metformin.

Ebymect is used:

on its own in patients whose disease is not controlled well enough with metformin alone;
in combination with other diabetes medicines when these medicines together with metformin are not controlling the diabetes well enough.

Ebymect can also be used to replace dapagliflozin and metformin taken as separate tablets.

: Ebymect is available as tablets containing 5 mg of dapagliflozin with 850 mg of metformin and as 5 mg of dapagliflozin with 1,000 mg of metformin. The recommended dose is 1 tablet taken twice a day with a meal; the strength should be chosen so that in total, patients receive 10 mg of dapagliflozin each day and the same (or almost the same) dose of metformin they were taking before starting Ebymect.
When Ebymect is added to treatment with insulin or a medicine that helps the body to produce insulin, such as a sulphonylurea, the doctor may need to lower the dose of insulin or sulphonylurea to prevent hypoglycaemia (low blood sugar levels).
The medicine can only be obtained with a prescription. For further information about using Ebymect, see the package leaflet or contact your doctor or pharmacist.

Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the amount of glucose (sugar) in the blood or when the body cannot use insulin effectively. This leads to high levels of glucose in the blood.

Ebymect contains two different active substances, which work in different ways:

dapagliflozin blocks the action of a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2). As blood is filtered by the kidneys, SGLT2 stops glucose in the bloodstream from being passed out into the urine. By blocking the action of SGLT2, dapagliflozin causes the kidneys to pass out more glucose in the urine, thereby reducing the levels of glucose in the blood. Dapagliflozin has been authorised in the European Union (EU) as Forxiga since 2012;
metformin works mainly by reducing glucose production and reducing its absorption from the gut. It has been available in the EU since the 1950s.

As a result of the action of both active substances, the blood glucose is reduced and this helps to control type 2 diabetes.

: Dapagliflozin in combination with metformin was evaluated in 6 main studies involving 3,200 adults with type 2 diabetes. The majority of these data had already been used in the authorisation of Forxiga.
In one main study, when dapagliflozin was used at a dose of 5 mg twice a day in addition to metformin (the same combination as in Ebymect), it decreased HbA1c (glycosylated haemoglobin) levels by 0.65% after 16 weeks, compared with a reduction of 0.30% with placebo (a dummy treatment) and metformin. HbA1c is a substance in the blood which gives an indication of how well the blood glucose is controlled.
Two other studies showed that dapagliflozin taken with metformin and another diabetes medicine, sitagliptin or insulin, for 24 weeks, further decreased HbA1c: the dapagliflozin combination decreased HbA1c levels by 0.40% more than placebo and metformin when added to sitagliptin, and by 0.61% more than placebo and metformin when added to insulin.
Further studies confirmed that different doses of dapagliflozin with metformin decreased HbA1c more than placebo plus comparable doses of metformin, and that dapagliflozin plus metformin was at least as effective in reducing HbA1c levels as the diabetes medicine glipizide (a type of medicine known as a sulphonylurea).
One study showed that after 24 weeks of treatment, patients taking dapagliflozin plus metformin had an average reduction in body weight of around 2 kg more than those taking placebo plus metformin.
A long-term study, involving over 17,000 patients with type 2 diabetes, looked at the effects of dapagliflozin on cardiovascular (heart and circulation) disease. The study indicated that dapagliflozin's effects were in line with those of other diabetes medicines that also work by blocking SGLT2.

The most common side effects with Ebymect (which may affect more than 1 in 10 people) are hypoglycaemia (when used together with insulin or a sulphonylurea) and gastrointestinal symptoms (symptoms affecting the stomach and gut). For the full list of side effects with Ebymect, see the package leaflet.

Ebymect must not be used in:

patients with any form of acute metabolic acidosis (build up of acid in the blood), such as diabetic

ketoacidosis (high blood levels of acids called ketones) or lactic acidosis (build-up of lactic acid in
the body);
patients with diabetic pre-coma (a dangerous condition that can occur in diabetes);
patients with reduced liver function;
patients with severe reduction in kidney function or with conditions that could alter kidney function,
such as dehydration, severe infection or shock;
patients with diseases that could cause tissue hypoxia (reduced levels of oxygen in body tissues),
such as heart or lung failure (where the heart and lungs do not work as well as they should),
recent heart attack or shock;
patients who are intoxicated with alcohol (drunkenness) or who regularly drink excessive amounts of alcohol.

For the full list of restrictions, see the package leaflet.

: The European Medicines Agency decided that Ebymect’s benefits are greater than its risks and recommended that it can be authorised for use in the EU. The Agency considered Ebymect to be effective for treating type 2 diabetes; it also leads to weight loss, which is considered beneficial in patients with diabetes. The Agency also noted that giving the combination of dapagliflozin and metformin as a single tablet could provide an additional treatment option for patients with type 2 diabetes, and may improve adherence to treatment. Regarding its safety profile, this was considered similar to the safety profile of dapagliflozin.

: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ebymect have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Ebymect are continuously monitored. Side effects reported with Ebymect are carefully evaluated and any necessary action taken to protect patients.

: Ebymect received a marketing authorisation valid throughout the EU on 15 November 2015.
This authorisation was based on the authorisation granted to Xigduo in 2014 (‘informed consent’).

List item

Ebymect : EPAR - Medicine overview (PDF/86.24 KB)

First published: 23/11/2015
Last updated: 28/08/2019
EMA/467741/2019
- Bulgarian
  (PDF/148.92 KB)
- Croatian
  (PDF/142.53 KB)
- Czech
  (PDF/145.06 KB)
- Danish
  (PDF/119.9 KB)
- Dutch
  (PDF/120.7 KB)
- Estonian
  (PDF/116.35 KB)
- Finnish
  (PDF/116.91 KB)
- French
  (PDF/122.88 KB)
- German
  (PDF/124.74 KB)
- Greek
  (PDF/148.76 KB)
- Hungarian
  (PDF/144.5 KB)
- Italian
  (PDF/119.08 KB)
- Latvian
  (PDF/139.92 KB)
- Lithuanian
  (PDF/142.96 KB)
- Maltese
  (PDF/143.99 KB)
- Polish
  (PDF/148.12 KB)
- Portuguese
  (PDF/121.69 KB)
- Romanian
  (PDF/140.44 KB)
- Slovak
  (PDF/145.34 KB)
- Slovenian
  (PDF/141.83 KB)
- Spanish
  (PDF/120.34 KB)
- Swedish
  (PDF/118.32 KB)
List item

Ebymect : EPAR - Risk-management-plan summary (PDF/174.94 KB)

First published: 23/11/2015
Last updated: 28/08/2019

This EPAR was last updated on 06/03/2023

Authorisation details

Product details
Name	Ebymect
Agency product number	EMEA/H/C/004162
Active substance	dapagliflozin propanediol monohydrate metformin hydrochloride
International non-proprietary name (INN) or common name	dapagliflozin metformin
Therapeutic area (MeSH)	Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code	A10BD15

Publication details
Marketing-authorisation holder	AstraZeneca AB
Revision	18
Date of issue of marketing authorisation valid throughout the European Union	15/11/2015
Contact address	151 85 Sodertalje Sweden

Product information

06/02/2023 Ebymect - EMEA/H/C/004162 - WS/2382

List item

Ebymect : EPAR - Product Information (PDF/741.99 KB)

First published: 23/11/2015
Last updated: 06/03/2023
- Bulgarian
  (PDF/493.54 KB)
- Croatian
  (PDF/450.81 KB)
- Czech
  (PDF/437.77 KB)
- Danish
  (PDF/438.3 KB)
- Dutch
  (PDF/867.1 KB)
- Estonian
  (PDF/391.54 KB)
- Finnish
  (PDF/624.38 KB)
- French
  (PDF/547.75 KB)
- German
  (PDF/436.08 KB)
- Greek
  (PDF/544.68 KB)
- Hungarian
  (PDF/498.88 KB)
- Icelandic
  (PDF/340.46 KB)
- Italian
  (PDF/471.57 KB)
- Latvian
  (PDF/660.29 KB)
- Lithuanian
  (PDF/389.89 KB)
- Maltese
  (PDF/492.4 KB)
- Norwegian
  (PDF/678.62 KB)
- Polish
  (PDF/506.82 KB)
- Portuguese
  (PDF/523.03 KB)
- Romanian
  (PDF/761.2 KB)
- Slovak
  (PDF/499.56 KB)
- Slovenian
  (PDF/565.82 KB)
- Spanish
  (PDF/372.37 KB)
- Swedish
  (PDF/744.12 KB)

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

List item

Ebymect : EPAR - All Authorised presentations (PDF/30.47 KB)

First published: 23/11/2015
Last updated: 22/09/2020
- Bulgarian
  (PDF/33.82 KB)
- Croatian
  (PDF/31.28 KB)
- Czech
  (PDF/30.95 KB)
- Danish
  (PDF/29.48 KB)
- Dutch
  (PDF/54.57 KB)
- Estonian
  (PDF/30.68 KB)
- Finnish
  (PDF/30.8 KB)
- French
  (PDF/25.97 KB)
- German
  (PDF/31.54 KB)
- Greek
  (PDF/33.77 KB)
- Hungarian
  (PDF/39.74 KB)
- Icelandic
  (PDF/31.24 KB)
- Italian
  (PDF/31.14 KB)
- Latvian
  (PDF/32.77 KB)
- Lithuanian
  (PDF/32.97 KB)
- Maltese
  (PDF/41.71 KB)
- Norwegian
  (PDF/31.62 KB)
- Polish
  (PDF/42.33 KB)
- Portuguese
  (PDF/30.96 KB)
- Romanian
  (PDF/30.64 KB)
- Slovak
  (PDF/45.21 KB)
- Slovenian
  (PDF/43.39 KB)
- Spanish
  (PDF/53.4 KB)
- Swedish
  (PDF/31.78 KB)

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Type 2 diabetes mellitus

For the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

as monotherapy when metformin is considered inappropriate due to intolerance.
in addition to other medicinal products for the treatment of type 2 diabetes.

For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Type 1 diabetes mellitus

Edistride is indicated in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

Assessment history

Changes since initial authorisation of medicine

List item

Ebymect : EPAR - Procedural steps taken and scientific information after authorisation (PDF/262.85 KB)

First published: 26/05/2016
Last updated: 06/03/2023
List item

Ebymect-H-C-4162-WS-1539 : EPAR - Assessment report - Variation (PDF/1.45 MB)

Adopted

First published: 28/08/2019
EMA/476671/2019
List item

CHMP post-authorisation summary of positive opinion for Ebymect (WS1539/0035) (PDF/67.64 KB)

Adopted

First published: 28/06/2019
EMA/CHMP/365312/2019
List item

Ebymect-H-A20-1442-C-4162-0013 : EPAR - Assessment Report - Article 20 (PDF/254.07 KB)

Adopted

First published: 05/07/2017
Last updated: 05/07/2017
EMA/PRAC/637349/2016
List item

Ebymect-H-A20-1442-C-4162-0013 : EPAR - Scientific Conclusion - Article 20 (PDF/41.36 KB)

First published: 05/07/2017
Last updated: 05/07/2017
- Bulgarian
  (PDF/84.18 KB)
- Croatian
  (PDF/76.27 KB)
- Czech
  (PDF/78.08 KB)
- Danish
  (PDF/41.03 KB)
- Dutch
  (PDF/42.37 KB)
- Estonian
  (PDF/40.46 KB)
- Finnish
  (PDF/40.53 KB)
- French
  (PDF/42.93 KB)
- German
  (PDF/44.39 KB)
- Greek
  (PDF/84.71 KB)
- Hungarian
  (PDF/60.56 KB)
- Icelandic
  (PDF/40.74 KB)
- Italian
  (PDF/40.72 KB)
- Latvian
  (PDF/76.13 KB)
- Lithuanian
  (PDF/72.25 KB)
- Maltese
  (PDF/83.36 KB)
- Norwegian
  (PDF/40.5 KB)
- Polish
  (PDF/62.96 KB)
- Portuguese
  (PDF/42.06 KB)
- Romanian
  (PDF/78.32 KB)
- Slovak
  (PDF/70.79 KB)
- Slovenian
  (PDF/75.63 KB)
- Spanish
  (PDF/41.99 KB)
- Swedish
  (PDF/41.68 KB)
List item

Ebymect-H-C-4162-A31-1432 : EPAR - Assessment Report - Article 31 (PDF/568.79 KB)

Adopted

First published: 21/12/2016
Last updated: 21/12/2016
EMA/867221/2016
List item

Ebymect : EPAR - Scientific Conclusion (PDF/25.92 KB)

First published: 21/12/2016
Last updated: 21/12/2016

Ebymect

Table of contents

Overview

Ebymect : EPAR - Medicine overview (PDF/86.24 KB)

Ebymect : EPAR - Risk-management-plan summary (PDF/174.94 KB)

Authorisation details

Product information

Ebymect : EPAR - Product Information (PDF/741.99 KB)

Ebymect : EPAR - All Authorised presentations (PDF/30.47 KB)

Pharmacotherapeutic group

Therapeutic indication

Assessment history

Changes since initial authorisation of medicine

Ebymect : EPAR - Procedural steps taken and scientific information after authorisation (PDF/262.85 KB)

Ebymect-H-C-4162-WS-1539 : EPAR - Assessment report - Variation (PDF/1.45 MB)

CHMP post-authorisation summary of positive opinion for Ebymect (WS1539/0035) (PDF/67.64 KB)

Ebymect-H-A20-1442-C-4162-0013 : EPAR - Assessment Report - Article 20 (PDF/254.07 KB)

Ebymect-H-A20-1442-C-4162-0013 : EPAR - Scientific Conclusion - Article 20 (PDF/41.36 KB)

Ebymect-H-C-4162-A31-1432 : EPAR - Assessment Report - Article 31 (PDF/568.79 KB)

Ebymect : EPAR - Scientific Conclusion (PDF/25.92 KB)

Initial marketing-authorisation documents

Ebymect : EPAR - Public assessment report (PDF/255.67 KB)

CHMP summary of positive opinion Ebymect (PDF/74.92 KB)

News

Related content

How useful was this page?